RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Fresenius SE & Co KGaA Stocks 2024

Fresenius SE & Co KGaA Stocks

563.24 M

Fresenius SE & Co KGaA Dividend yield

3.21 %

Ticker

FRE.DE

ISIN

DE0005785604

WKN

578560

In 2024, Fresenius SE & Co KGaA had 563.24 M outstanding stocks, a 0% change from the 563.24 M stocks in the previous year.

The Fresenius SE & Co KGaA Stocks history

YEARNUMBER OF STOCKS (undefined EUR)
2028e563.24
2027e563.24
2026e563.24
2025e563.24
2024e563.24
2023563.24
2022561.26
2021558.16
2020557.74
2019557.42
2018557.3
2017557.51
2016550.08
2015548.16
2014544.3
2013540
2012524
2011493
2010488
2009485
2008477
2007469
2006464
2005380
2004379

Fresenius SE & Co KGaA Aktienanalyse

What does Fresenius SE & Co KGaA do?

Fresenius SE is a German pharmaceutical and medical technology company, which was founded in 1912 by Eduard Fresenius. The company's history is marked by continuous growth and numerous acquisitions, which have shaped the current corporate structure. Fresenius operates in four different divisions: Fresenius Medical Care is a global leader in dialysis treatment and offers products as well as services related to dialysis. Fresenius Kabi specializes in the production of medications and medical devices for infusion and nutrition therapy. Fresenius Helios is one of the largest providers of hospital treatments with over 110 clinics and operates facilities in Germany, Spain, and Latin America. Fresenius Vamed offers services related to the management and planning of healthcare facilities and operates worldwide in over 85 countries. The business model of Fresenius SE is based on the development and production of innovative medical products, as well as the provision of services in the healthcare sector. The company relies on high-quality products and intensive research and development. A key factor for success is focusing on the needs of customers and patients to ensure the best possible care. One of the most well-known products of Fresenius SE are the Fresenius concentrates for dialysis treatment. These enable effective and gentle blood cleansing, thereby improving the quality of life for dialysis patients. Another example of innovative products are the 3-in-1 infusion systems by Fresenius Kabi. These combine the administration of fluids, medications, and nutrition into one system, offering significantly higher efficiency in patient care. Fresenius Helios focuses on patient-centered care and offers a wide range of medical services. The company operates both acute care clinics and long-term care facilities and utilizes state-of-the-art technologies to improve diagnosis and treatment. Fresenius Vamed provides its customers with services such as facility management, planning, and project management for healthcare facilities, as well as operational consulting. The comprehensive expertise in all areas of the healthcare industry ensures high quality in the implementation of construction projects and renovations. In summary, Fresenius SE is an internationally active company specializing in the provision of high-quality products and services in the healthcare sector. The company focuses on patient-centered care and the continuous development of innovative products and technologies. Fresenius SE & Co KGaA ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Fresenius SE & Co KGaA revenue by segment

In the annual report of the Fresenius SE & Co KGaA share (DE0005785604, 578560, FRE.DE), it breaks down its revenues into 4 segments: 1. Helios, 2. Kabi, 3. Vamed, 4. Medical Care. The Fresenius SE & Co KGaA stock (WKN: 578560, ISIN: DE0005785604, Ticker Symbol: FRE.DE) is a leading investment for investors interested in participating in the Health Care sector.

Stocks Details

Evaluating Fresenius SE & Co KGaA's Shares Outstanding

Fresenius SE & Co KGaA's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Fresenius SE & Co KGaA’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Fresenius SE & Co KGaA’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Fresenius SE & Co KGaA’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Fresenius SE & Co KGaA Stock

How many stocks are there of Fresenius SE & Co KGaA?

The current number of stocks of Fresenius SE & Co KGaA is 563.24 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Fresenius SE & Co KGaA are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Fresenius SE & Co KGaA evolved in recent years?

The number of shares of Fresenius SE & Co KGaA has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Fresenius SE & Co KGaA as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Fresenius SE & Co KGaA?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Fresenius SE & Co KGaA pay?

Over the past 12 months, Fresenius SE & Co KGaA paid a dividend of 0.92 EUR . This corresponds to a dividend yield of about 3.21 %. For the coming 12 months, Fresenius SE & Co KGaA is expected to pay a dividend of 0.96 EUR.

What is the dividend yield of Fresenius SE & Co KGaA?

The current dividend yield of Fresenius SE & Co KGaA is 3.21 %.

When does Fresenius SE & Co KGaA pay dividends?

Fresenius SE & Co KGaA pays a quarterly dividend. This is distributed in the months of June, June, June, June.

How secure is the dividend of Fresenius SE & Co KGaA?

Fresenius SE & Co KGaA paid dividends every year for the past 25 years.

What is the dividend of Fresenius SE & Co KGaA?

For the upcoming 12 months, dividends amounting to 0.96 EUR are expected. This corresponds to a dividend yield of 3.35 %.

In which sector is Fresenius SE & Co KGaA located?

Fresenius SE & Co KGaA is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fresenius SE & Co KGaA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fresenius SE & Co KGaA from 5/22/2023 amounting to 0.92 EUR, you needed to have the stock in your portfolio before the ex-date on 5/18/2023.

When did Fresenius SE & Co KGaA pay the last dividend?

The last dividend was paid out on 5/22/2023.

What was the dividend of Fresenius SE & Co KGaA in the year 2023?

In the year 2023, Fresenius SE & Co KGaA distributed 0.66 EUR as dividends.

In which currency does Fresenius SE & Co KGaA pay out the dividend?

The dividends of Fresenius SE & Co KGaA are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Fresenius SE & Co KGaA stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Fresenius SE & Co KGaA

Our stock analysis for Fresenius SE & Co KGaA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fresenius SE & Co KGaA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.